TITLE

Overseas Tax Savings for US Drugmakers Under Threat

PUB. DATE
March 2013
SOURCE
MondayMorning;3/18/2013, Vol. 21 Issue 10, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses the tax savings by the U.S. drug manufacturing companies by shifting ownership of trademark and patents in countries with less or no tax. Also discussed is the possibility of tax reform in the U.S. which is expected to return profits from corporate world for job creation and investment. Various companies which are shifting profits include Merck & Co. Inc., Pfizer Inc. and Johnson and Johnson.
ACCESSION #
86435097

 

Related Articles

  • Pharma: Other News To Note.  // BioWorld Today;5/23/2013, Vol. 24 Issue 99, p10 

    This section offers news briefs on pharmaceutical financing including the signing of an accelerated share repurchase (ASR) agreement by Merck & Co. Inc. with finance firm Goldman Sachs & Co. and the splitting off via an exchange offer of the remaining interest of Pfizer Inc. in Zoetis Inc.

  • Quarterly Reports.  // Contract Pharma;Mar2013, Vol. 15 Issue 2, p133 

    The article discusses the revenues and earnings of several pharmaceutical industries for 2012. Pfizer Inc.'s revenues in the U.S. were 9% down due to the loss of exclusivity for Lipitor and Geodon drugs. Merck & Co. Inc.'s sales were 6% down due to foreign exchange. AstraZeneca PLC's revenues...

  • Pullback As Payback.  // njbiz;9/1/2003, Vol. 16 Issue 35, p3 

    Reports on the announcement by Merck and Pfizer in August 2003 that they will be cutting back research activities in Germany. Reason behind their plans; Overview of their plans.

  • CHAPTER 92: LARGEST PHARMACEUTICAL COMPANIES. Miller, Richard K.; Washington, Kelli // Healthcare Business Market Research Handbook;2013, p387 

    A list of the top pharmaceutical corporations in 2011-2012, ranked by U.S. and global prescription sales, is presented including Pfizer, AstraZeneca and Merck & Co.

  • Pfizer, Merck Explore Cancer Therapies.  // Chain Drug Review;2/17/2014, Vol. 36 Issue 4, p46 

    The article reports that drug manufactuirng companies Pfizer Inc. and a pair of Merck & Co. subsidiaries have collaborated to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two oncology assets of Pfizer.

  • Merck, Pfizer Exceed Expectations.  // Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p8 

    The article reports on the financial performance of Pfizer Inc. and Merck & Co. Inc. in 2010.

  • Merck, Pfizer collaborate on anti-cancer immunotherapy.  // BioSpectrum;Dec2014, Vol. 12 Issue 12, p12 

    The article reports on the agreement between Pfizer and Merck & Co. aimed for the exploration of the therapeutic potential of the combination of Pfizer's crizotinib with Merck's anti-PD-1 pembrolizumab.

  • Merck, Pfizer tie up for diabetes research.  // BioSpectrum;Jun2013, Vol. 11 Issue 6, p80 

    The article reports on the collaboration agreement between Merck & Co. Inc. and Pfizer Inc., which was intended for the development and marketing of ertugliflozin for type 2 diabetes treatment.

  • Drug Sponsors.  // CenterWatch Weekly;11/30/2015, Vol. 19 Issue 47, p2 

    The article offers updates including the definitive agreement between Pfizer Inc. and Allergan PLC, the launching of Boston Pharmaceuticals, and the planned expansion of Merck & Co. Inc. to the African continent.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics